BioVision Lilly Award to honour scientists from developing countries
Prize will reward research into infectious diseases
The prize will reward three young scientists living and working in a developing country, who have a track record of excellent research in infectious diseases, preferably with an emphasis on tuberculosis, and promise to have a positive impact in the developing world.
Candidates should be under 40 and hold at least a PhD.
Three winners will be selected and invited to attend BioVision 2011 in Lyon, France from 27-29 March.
The winner will receive US$5,000 and the runner-up $2,000, to be used for his or her research. The third prizewinner will receive an invitation to attend BioVision 2011, with travel and hotel costs paid.
The awards will be presented at a ceremony hosted by BioVision, TWAS and Lilly, during the exhibition.
The closing date for nominations is 15 January 2011.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
The path to commercial allogeneic iPSC therapies
The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development
Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies
Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Research & Development
Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation
New GS Ori‑Go vector technology supports titers higher than 11 g/L and reliable bulk pool stability, enabling more predictable material generation and shortened cell line development timelines
Manufacturing
Bruker announces major strides in 4D proteomics performance, further advances In intact and top-down functional proteoform analysis, and innovations in hybrid qual/quant 4D metabolomics
All to enable deeper insights into disease biology. Bruker Also Launches Two Novel Mass Spectrometry Systems for Unique Applications in Energy Industry Research, and in Semiconductor Manufacturing